The Manufacturers Life Insurance Company Raises Stake in Bristol Myers Squibb Company $BMY

Posted by George Bondi on Jul 29th, 2026

The Manufacturers Life Insurance Company increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 15.8% in the first quarter, Holdings Channel reports. The firm owned 1,766,418 shares of the biopharmaceutical company’s stock after acquiring an additional 241,405 shares during the period. The Manufacturers Life Insurance Company’s holdings in Bristol Myers Squibb were worth $107,133,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BMY. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. raised its stake in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the period. Bayban acquired a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY opened at $63.65 on Wednesday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $64.96. The firm has a market cap of $129.97 billion, a price-to-earnings ratio of 17.88, a PEG ratio of 0.18 and a beta of 0.23. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a fifty day simple moving average of $57.70 and a 200 day simple moving average of $58.17.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s payout ratio is 70.79%.

Analysts Set New Price Targets

Several analysts recently issued reports on BMY shares. Bank of America lowered their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Cantor Fitzgerald restated a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research note on Monday, July 6th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Guggenheim reiterated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $61.25.

View Our Latest Analysis on Bristol Myers Squibb

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.